Study wrapper · #1360
What obgyns need to know about GLP-1 receptor agonists.
Editor's note
A single-author narrative review, but one addressing questions with real practical stakes for reproductive-aged women, who make up a large share of GLP-1 users. The contraception interaction with tirzepatide and the preconception-discontinuation guidance are drawn from manufacturer labeling and emerging cohort data rather than dedicated trials. The call for pregnancy registries is well placed — the human exposure data remain thin.
Plain-language abstract
A review for obstetrician-gynecologists on GLP-1 drugs in women's health, covering 15-21% weight loss in phase 3 trials, improvements in PCOS markers and ovulation, the advice to use backup contraception for four weeks after starting or escalating tirzepatide, and early reassuring data on accidental pregnancy exposure.